| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 0.6% | 5.1% | 18.0% |
| 2025 |
|---|
| 18.0% |
The Northern Large Cap Value Fund outperformed its Russell 1000 Value benchmark in Q4 2025, returning 5.06% versus 3.81% for the index. The fund's investment approach focuses on attractively valued stocks with strong peer-relative profitability, cash flows, and management efficiency. During the quarter, value stocks significantly outperformed across both the R1000 Index and R1000 Value Index, benefiting the fund's value-oriented strategy. The fund's tilt towards high-quality stocks also contributed positively to performance. Healthcare was the best performing sector in the value index, led by pharmaceutical and biotechnology companies, while defensive sectors like real estate and utilities underperformed. Sector allocation modestly added to relative performance, though stock selection detracted. The manager maintains a constructive outlook, planning to continue seeking exposure to diverse, high-quality, inexpensive companies. They believe high-quality fundamentals at attractive valuations will continue to stand out in the market environment.
The fund invests in attractively valued large-cap stocks with strong fundamentals, emphasizing quality characteristics like peer-relative profitability, cash flows, and management efficiency.
Looking ahead, we will continue to seek exposure to a diverse group of high-quality, inexpensive companies. We believe the importance of high quality company fundamentals, particularly those trading at attractive valuations, will stand out and the Fund should benefit accordingly.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Feb 5 2026 | 2025 Q4 | NOLVX | healthcare, large cap, Pharmaceuticals, Quality, value | - | The fund invests in attractively valued stocks with strong peer-relative profitability, cash flows, and management efficiency. Value stocks significantly outperformed in both R1000 Index and R1000 Value Index during the quarter. The fund's value tilt added to performance. The fund tilts towards high quality stocks which slightly added to performance during the quarter. High quality stocks outperformed the R1000 Value index. The manager emphasizes the importance of high quality company fundamentals. |
| Nov 11 2025 | 2025 Q3 | - | AI, large cap, Outperformance, Quality, technology, value | - | Value stocks outperformed as high-quality, cash-generative U.S. companies benefited from resilient economic data and easing financial conditions. The funds tilt toward strong profitability, efficient management, and attractive valuations provided a performance edge over the benchmark. Management remains focused on diversified exposure to durable, undervalued franchises positioned for cyclical and structural recovery. |
| Jul 31 2025 | 2025 Q2 | - | cash flow, profitability, Quality, valuation, value | - | The commentary emphasizes value investing grounded in profitability, cash flow strength, and management efficiency during a period of market concentration in megacap growth stocks. Management argues that normalized valuation metrics and quality tilts improve long-term outcomes despite short-term underperformance. The fund is positioned for valuation discipline to reassert itself as market leadership broadens. |
| Mar 31 2025 | 2025 Q1 | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
QualityThe company emphasizes investing in businesses with excellent economics, durable competitive advantages, and high-integrity management. This quality focus is evident in concentrated equity holdings and operating business acquisitions. |
Durable Advantages Management Quality Economic Moats Competitive Position |
ValueManager emphasizes investing in controlled companies trading at significant discounts to NAV, with European holding companies showing discounts of 30-68%. The strategy focuses on securities mispricing where real value exists, contrasting with overvalued technology stocks. |
Discounts NAV Mispricing Undervalued Controlled | |
| 2025 Q3 |
AIAI has been integrated into RGA's research process through tools like NotebookLM, Gems in Gemini, and Claude Code. The firm views AI as a force multiplier for human judgment rather than a replacement, emphasizing the Kasparov Law principle. They believe the market narrative around AI displacement is swinging to unhelpful extremes, creating investment opportunities. |
Machine Learning Automation Software Productivity Innovation |
QualityThe company emphasizes investing in businesses with excellent economics, durable competitive advantages, and high-integrity management. This quality focus is evident in concentrated equity holdings and operating business acquisitions. |
Durable Advantages Management Quality Economic Moats Competitive Position | |
ValueManager emphasizes investing in controlled companies trading at significant discounts to NAV, with European holding companies showing discounts of 30-68%. The strategy focuses on securities mispricing where real value exists, contrasting with overvalued technology stocks. |
Discounts NAV Mispricing Undervalued Controlled | |
| 2025 Q2 |
ValueThe manager continues to find attractive value opportunities despite expensive markets, purchasing undervalued companies like Centene, GlaxoSmithKline, Carrefour and PayPal trading at low multiples with strong fundamentals. |
Undervalued Low Multiples Contrarian Opportunistic |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| No Elevator Pitches found | ||||||||||
| TICKER | COMMENTARY |
|---|
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||
